Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TETON-2 phase 3 trial of inhaled treprostinil in idiopathic pulmonary fibrosis
MOH_2022-10-24_012136Phase 3Not yet recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Inhaled treprostinil with Placebo (2 arms). Planned start Sep 2022; status: not yet recruiting.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2022-10-24_012136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-24_012136.